… role of BRAF/MEK inhibitors in the treatment of this disease. We describe the recent development
of the selective MEK inhibitor binemetinib in the treatment of metastatic melanoma, and …

… MEK + CDK4 inhibition: An inducible mouse model of NRAS-mutant melanoma demonstrated
that MEK inhibition was sufficient to cause apoptosis but not cell cyle arrest. In contrast, …

… of MEK inhibition and CDK4/6 inhibition is … melanoma cell lines where BRAF inhibitor
resistance is mediated through an acquired NRAS mutation, the combination of a MEK inhibitor …

… in the MAPK pathway and MEK inhibitors have shown significant growth inhibitory effects in
some BRAF and NRAS mutant melanoma cells [12,13]. BRAF mutant cell lines usually show …

… A total of 364 patients were included in this study, 236 patients with NRAS mutant melanoma
and 128 patients with NRAS wildtype melanoma (Table 1). Known prognostic markers …

… Selective MEK inhibitors have the ability to inhibit growth and induce cell death in BRAF- …
NRAS-mutant melanoma cell lines. MEK inhibitor therapy in combination with a BRAF inhibitor …

… NRAS mutant melanoma comprises 20% of all melanoma, … BRAF-mutant or RAF and NRAS
wild-type melanomas. Citation… increase MEK inhibitors’ efficacy in NRAS-mutant melanoma …

… in NRAS mutant melanoma when MEK is inhibited. However, targeting of PI3K/mTOR 1,2
in … with MEK inhibitors is necessary to effectively abolish growth of NRAS mutant melanoma …

… Although other MEK inhibitors have failed to demonstrate clinical activity in N-RAS mutant
melanoma, our findings support further studies of MEK inhibition in this patient population, …

… treatment in a real-world setting of patients with highly advanced NRAS-mutated melanoma.
In our patient cohort, MEK inhibition was initiated after in median two lines of treatment and …